The FDA has accepted an sBLA for glofitamab plus gemcitabine and oxaliplatin in relapsed/refractory diffuse large B-cell ...
Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance ...
CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...
Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed ...
During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of ...
Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...
During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...
Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.